Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Arnaud

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Therapie|August 20, 2011
[Precompetitive research, a synergy of public and private resources: for what purpose, how and in what framework?]Gilles Vassal, Carole Neves, Olivier Arnaud, et al.
Therapie|July 10, 2016
[Not Available]Gilles Vassal, Carole Neves, Olivier Arnaud, et al.
BMJ Open|December 8, 2021
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetesCharlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Therapie|August 20, 2011
[Precompetitive research, a synergy of public and private resources: for what purpose, how and in what framework?]Gilles Vassal, Carole Neves, Olivier Arnaud, et al.
Therapie|July 10, 2016
[Not Available]Gilles Vassal, Carole Neves, Olivier Arnaud, et al.
BMJ Open|December 8, 2021
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetesCharlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, et al.
Pageof 1